Full-Time

Senior Medical Director

Oncology/Hematology

Posted on 11/23/2025

IQVIA

IQVIA

10,001+ employees

Analytics, technology, and clinical research services.

Compensation Overview

$186.3k - $519k/yr

+ Bonuses + Incentive plans

Company Historically Provides H1B Sponsorship

Durham, NC, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
Google Cloud Platform
Responsibilities
  • Functions as project team member
  • Provides medical and scientific input to clinical research programs including review of new business proposals, preclinical and/or clinical data, study protocols, training materials, informed consent, Investigator Drug Brochures, eCRFs, analysis plan designs, clinical study reports, regulatory approval submissions, serious and non-serious adverse event evaluation and reporting
  • Ensures medical activities run according to GCP and operate with highest efficiency
  • Establishes and maintains a network of medical/scientific consultants, etc.
  • Supervises and manages Medical Director activities
  • Interacts with clients regarding drug development programs, study design and protocol
  • Reviews and provides input for protocol development. Interacts with key thought leaders and/or sponsor representatives to develop inclusion/exclusion criteria and study endpoints. Interacts in team approach to develop statistical and data management sections of the protocol. Reviews the final protocol for clinical, safety and efficacy variables
  • Provides project team training on protocol and/or therapeutic areas
  • Assists team with developing criteria for investigator site selection and networking for potential investigators for study participation. Aids in review and final selection
  • Participates in subject recruitment and retention activities including individual calls to key opinion leaders, investigators and site staff and/or participation in teleconference and WebEx presentations
  • Presents protocol and/or safety reporting information at investigator meetings
  • Develops project medical monitoring plans as requested
  • Provides on call coverage for protocol queries and site support. Provides first line contact for investigators and monitors regarding study related medical/safety issues and resolution of study protocol and patient eligibility issues
  • Verifies the medical accuracy of patient safety data and maintains an ongoing assessment of the safety profile of the study
  • Provides medical review of SAE reporting, writes and/or reviews SAE narratives, and works with the Safety Management Department to track SAEs and follow-up on outstanding safety queries, interacts with sponsor and discusses safety issues with site as needed
  • Reviews IND/SUSAR Safety Reports (per sponsor preference), updates to Investigator Brochures, and annual IND reports with sponsor data
  • In consultation with the sponsor, follow procedures for acquiring knowledge of subject treatment assignments (i.e. breaking the blind)
  • Interact with appropriate FDA officials concerning safety and other study related issues, as requested
  • Provides medical review of eCRFs for clinical accuracy
  • Provides medical review of data analysis plan
  • Reviews safety fields at case freeze for reconciliation (if needed)
  • Works with data group to reconcile SAE events as needed
  • Reviews medical coding of adverse events, laboratory data and concomitant medications for accuracy, coherence, consistency, and trends
  • Reviews data tables, listings, and figures
  • Reviews and/or writes portions of final clinical study report
  • May assist sponsor in choosing committee members
  • May serve as a non-voting member to convene and organize proceedings
  • May develop operating guidelines in conjunction with committee members and submits these to sponsor for review
  • May determine data flow with sponsor to ensure reporting accuracy
  • Can ensure DSMB feedback is given to sites for IRBs
  • All DSMB activities are usually managed by the IQVIA Biotech Oversight Management Group and not the IQVIA Biotech medical monitor
  • Work with Business Development to actively solicit new business, including assistance with marketing presentations and proposal development
  • Supports business development activities with proposal development and sales presentations
  • Participates in feasibility discussions relating to specific project proposals
  • Obtain literature searches to acquire background information for study proposals, preparation of training sessions, and interpretation of clinical data, report writing, etc.
  • Assists with drafting of standard operating procedures and working practices regarding all Medical Director activities
  • Participate in a variety of team quality improvement efforts as necessary
  • Perform other related duties as assigned or requested by the Chief Medical Officer
Desired Qualifications
  • Board certification/eligibility ideal in Hematology/Oncology

IQVIA is a global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry. Its services combine deep clinical trial expertise with large datasets and analytics tools, delivered through the Connected Intelligence platform that links the healthcare ecosystem to generate insights while protecting patient privacy. The company differentiates itself by merging clinical research experience with expansive data resources and technology capabilities from its QuintilesIMS lineage, offering an integrated suite for faster research, development, and commercialization of medical treatments. IQVIA’s goal is to help pharmaceutical, biotech, and medical device companies, as well as researchers and governments, accelerate the development of new therapies and improve health outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue rose 8.4% to $4.15 billion, beating estimates.
  • Nineteen of the top 20 pharma companies already use IQVIA agents.
  • The Charles River discovery acquisition expands IQVIA into early-stage drug development.

What critics are saying

  • Pass-through mix weakness cut Q1 2026 book-to-bill to 1.04.
  • EBITDA margins fell 60 basis points from foreign exchange and pass-through headwinds.
  • IQVIA.ai depends on NVIDIA and faces copycat pressure before Q4 2026 releases.

What makes IQVIA unique

  • IQVIA fused Quintiles clinical execution with IMS Health data in 2016.
  • IQVIA.ai embeds agentic AI into regulated life-sciences workflows with NVIDIA.
  • IQVIA holds 100-plus AI patents and privacy-protected patient data.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at IQVIA who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Life Insurance

Flexible Work Hours

Paid Vacation

Wellness Program

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

0%
Yahoo Finance
Apr 10th, 2026
IQVIA gains 22.6% on AI platform launch, strategic acquisitions and sustainability progress

IQVIA Holdings has gained 22.6% over the past year, outperforming its industry's 5.8% growth. The company expects long-term earnings per share growth of 13%, with year-over-year growth of 11.6% in 2026 and 16.1% in 2027. IQVIA recently launched IQVIA.ai in collaboration with NVIDIA, integrating AI technologies into life sciences workflows. The platform combines analytics, automation and decision-making to improve efficiency and accelerate research, with strong early adoption from leading pharmaceutical companies. The company is expanding through strategic acquisitions, including drug discovery assets from Charles River Laboratories, adding in vitro services and AI-driven platforms. A partnership with Duke Clinical Research Institute aims to accelerate clinical research in obesity-related conditions, enhancing IQVIA's end-to-end offerings across the drug development lifecycle.

Yahoo Finance
Apr 5th, 2026
IQVIA launches unified agentic AI platform with Nvidia for life sciences

IQVIA Holdings has launched IQVIA.ai, a unified agentic AI platform developed in collaboration with Nvidia, specifically designed for the life sciences industry. The platform integrates IQVIA's healthcare-grade AI and data assets with Nvidia's technology stack, including Nemotron and the NeMo Agent Toolkit, to enhance operational efficiency across clinical, commercial and real-world domains. At launch, 19 of the top 20 pharmaceutical companies had already begun incorporating IQVIA's agents into their processes. The platform functions as a digital command centre, embedding intelligent agents directly into existing workflows whilst maintaining strict healthcare regulatory and privacy standards. IQVIA.ai features a catalogue of ready-to-use and configurable intelligent agents tailored for life sciences workflows. Additional agents and features are scheduled for release in Q4 2026.

IQVIA Holdings, Inc.
Mar 16th, 2026
IQVIA unveils IQVIA.ai, a unified agentic AI platform powered by NVIDIA to improve efficiency and decision making across Life Sciences.

IQVIA unveils IQVIA.ai, a unified agentic AI platform powered by NVIDIA to improve efficiency and decision making across Life Sciences. 03/16/2026 RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- IQVIA Holdings Inc. (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced at NVIDIA GTC the launch of IQVIA.ai, a unified agentic AI platform purpose-built to help life sciences organizations transform how they operate, make decisions and innovate across clinical, commercial and real-world domains. Combining IQVIA's deep life sciences expertise, Healthcare-grade AI(R) and data assets with NVIDIA Nemotron, NeMo Agent Toolkit, Dynamo and LangChain, IQVIA.ai is designed to continuously learn from complex operational feedback, while operating securely and in alignment with healthcare regulatory, privacy and quality standards - enabling responsible AI adoption at scale. IQVIA began its collaboration with NVIDIA more than a year ago to develop the agentic AI foundation that underpins IQVIA.ai. As part of this ongoing commitment to AI innovation, IQVIA has filed more than 100 AI-related patents and deployed more than 150 intelligent agents across internal teams and client environments. To date, 19 of the top 20 pharmaceutical companies have begun incorporating IQVIA agents into their workflows, underscoring broad industry trust in IQVIA's AI capabilities. Built on decades of IQVIA leadership at the intersection of data, technology and life sciences, IQVIA.ai represents a significant advancement in how AI is applied at enterprise scale. Unlike many standalone AI tools or horizontal AI platforms, IQVIA.ai enables organizations to embed intelligence directly into workflows, streamline complex operations and unlock greater value from data - while operating at the trust, quality and compliance levels demanded by regulated life sciences environments. IQVIA.ai serves as a digital command center that brings together AI-driven automation, advanced analytics and decision support within a single, unified experience. By orchestrating tasks and insights across multiple data sources and functions, the platform helps organizations accelerate research and analysis, improve operational efficiency and support more confident, timely decision making. IQVIA.ai combines conversational AI with an extensible catalog of intelligent agents, both ready-to-use and configurable, designed around real-world life sciences workflows. Through this single platform, customers can securely access, deploy and scale IQVIA powered AI tools, agents, insights and workflows, unifying intelligence and execution under one IQVIA-led architecture. "IQVIA.ai reflects our longstanding commitment to translating innovation into practical, high impact solutions for life sciences," said Bernd Haas, senior vice president, AI and Technology Solutions at IQVIA. "By bringing together our data, expertise and Healthcare-grade AI within a unified, agentic platform, IQVIA.ai enables organizations to move faster and smarter while meeting the rigorous standards of trust and reliability that are required in the industry." "The sheer volume and complexity of data within the life sciences industry have outpaced traditional methods of research and manual workflow," said Kimberly Powell, vice president of Healthcare and Life Sciences at NVIDIA. "By combining IQVIA's proprietary data and deep domain expertise with NVIDIA technology, IQVIA.ai provides the advanced agentic infrastructure needed to transform this data into actionable insights, enabling organizations to scale AI responsibly and accelerate the delivery of life-changing treatments." The initial release of IQVIA.ai will focus on high-value use cases across clinical, commercial and real-world, with additional agents and capabilities expected in Q4. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence(TM) to deliver actionable insights and services built on high quality health data, Healthcare grade AI(R), advanced analytics, the latest technologies, and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology, and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers, and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances in an effort to advance their path toward cures. To learn more, visit www.iqvia.com. Forward-Looking Statements This press release contains forward-looking statements based on current expectations, including statements regarding the expected capabilities, benefits and timing of IQVIA.ai and related offerings. These statements involve risks and uncertainties that could cause actual results to differ materially. Additional information about factors that could affect future results is contained in IQVIA's most recent filings with the Securities and Exchange Commission. IQVIA undertakes no obligation to update any forward-looking statements. Kerri Joseph, IQVIA Investor Relations [email protected] +1.973.541.3558 Multimedia Files:

Yahoo Finance
Mar 10th, 2026
IQVIA stock slides 28% from 52-week high as margin compression weighs on healthcare research giant

IQVIA Holdings, a Durham, North Carolina-based healthcare research company, has significantly underperformed the Nasdaq, falling 20.8% year-to-date and 6.8% over the past year, compared to the Nasdaq's 2.4% YTD decline and 24.7% annual gain. The $30.3 billion company, which provides analytics and clinical research services to the life sciences industry, has dropped 27.7% from its 52-week high of $247.05 reached on 9 January. Shares declined 10.7% on 5 February following fourth-quarter results, despite beating Wall Street expectations with adjusted earnings per share of $3.42 and revenue of $4.4 billion. The underperformance stems from margin compression and concerns about sustainability, as operating margins declined due to pass-through revenue growth and product mix changes.

PHARMPROM
Mar 5th, 2026
IQVIA Enters the Early-Stage Drug Development Market by Acquiring Charles River Laboratories Assets

IQVIA enters the early-stage drug development market by acquiring Charles River Laboratories assets. 06.03.2026 Contract research organization Charles River Laboratories has signed agreements to sell several of its divisions. The European early-stage drug development assets (Discovery Services) will be transferred to IQVIA, while the contract manufacturing (CDMO) business will be acquired by the investment firm GI Partners. Strategic motives: why IQVIA needs preclinical assets. The transaction reflects the transformation of IQVIA's business model. The company, historically specializing in healthcare data analytics and clinical trials (late phases), is expanding its presence in the earliest stages of drug creation. The perimeter of the deal includes five European research sites, an artificial intelligence platform for small molecule discovery, and New Approach Methodologies (NAMs) for animal-free testing. These assets have direct synergy with IQVIA's core analytical business: * Charles River's AI platform complements IQVIA's big data competencies, allowing the direct application of machine learning algorithms to model new molecules. * The acquisition allows IQVIA to offer pharmaceutical clients a continuous cycle of services: from molecule discovery and in vitro testing to clinical trials and drug commercialization. Financial parameters and transaction terms. The base value of the deal between Charles River and IQVIA is $145 million in cash, with the possibility of additional contingent payments of up to $10 million. The revenue of the acquired assets for 2025 was $144 million. Target therapeutic areas include oncology, neuroscience, immunology, and orphan diseases. The second agreement involves the sale of the CDMO and Cell Solutions divisions (manufacturing facilities in the US and the UK) to the investment company GI Partners. The structure of this transaction provides for contingent performance-based payments tied to the future financial results of the assets. The total revenue of these divisions in 2025 was $143 million. Implications for Charles River Laboratories. The divestiture of these divisions is part of Charles River's portfolio optimization. The sale of non-core assets will lead to a decrease in the company's reported revenue in 2026 by more than $200 million. At the same time, the restructuring will ensure an increase in the non-GAAP operating margin by at least 100 basis points, which allowed the company to raise its annual adjusted profit forecast. Both transactions are expected to close in the second quarter of 2026. Summary parameters of Charles River Laboratories M&A transactions. | Parameter | Value | | Seller | Charles River Laboratories | | Buyers | IQVIA Holdings Inc. and GI Partners | | Transaction rationale for IQVIA | Integration of early development (AI, in vitro) with clinical expertise | | IQVIA transaction value | $145 million in cash (+ up to $10 million in contingent payments) | | Assets for IQVIA | 5 research sites in Europe (2025 revenue: $144 million) | | GI Partners transaction terms | Contingent payments dependent on financial results | | Assets for GI Partners | CDMO and Cell Solutions divisions (2025 revenue: $143 million) | | Target closing date | Q2 2026 |

INACTIVE